|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.14/-0.78
|
Enterprise Value
278.47M
|
Balance Sheet |
Book Value Per Share
-1.06
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
146.03M
|
Operating Revenue Per Share
1.17
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 18:36 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States. |